Small Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMTTF research report →
About the company
Small Pharma Inc. is a biotechnology firm focused on developing fast-acting psychedelic therapies, coupled with supportive psychological care, to address mental health conditions. Its flagship clinical initiative centers on N,N-dimethyltryptamine (DMT) assisted therapy designed to combat major depressive disorder.
- CEO
- George Tziras
- IPO
- 2021
- HQ
- London, GB
Price Chart
- Market Cap
- $37.51M
- P/E
- -2.23
- P/S
- 0.00
- P/B
- 2.97
- EV/EBITDA
- -1.43
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -78.43%
- ROIC
- -128.32%
- Revenue
- $0 · 0.00%
- Net Income
- $-22,836,213 · -2.56%
- EPS
- $-0.07 · 0.70%
- Op Income
- $-24,680,068
- FCF YoY
- -36.88%
- 52W High
- $0.19
- 52W Low
- $0.04
- 50D MA
- $0.09
- 200D MA
- $0.07
- Beta
- 0.85
- Avg Volume
- 109.35K
Get TickerSpark's AI analysis on DMTTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DMTTF coverage
Recent articles, reports, and earnings notes.
No research on DMTTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMTTF report →Similar companies
Peers in the same neighborhood.